Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SMIM14 divergent transcript (SMIM14-DT) is a non-coding RNA transcript (probably a long non-coding RNA or lncRNA) located near the SMIM14 protein-coding gene, as catalogued by HGNC and rat genome databases[2][3]. Divergent transcripts are typically arranged head-to-head and are transcribed in the opposite direction from a nearby protein-coding gene. For SMIM14-DT, functional annotation is minimal, and there are no established roles in drug targeting or well-characterized biological processes[2][3]. While non-coding RNAs, including divergent transcripts, increasingly attract research attention for their possible regulatory roles in gene expression and disease, there is currently no direct evidence for SMIM14-DT's involvement in specific biological functions, disease roles, or drug interactions. SMIM14-DT is appropriately described as a long non-coding RNA transcript associated with the SMIM14 gene. It is not a receptor or classical drug target, is not misspelled, but is insufficiently characterized in terms of clinical or therapeutic relevance. All actionable data as a structured target (e.g., therapeutic classification, drug interactions, mechanism, biomarkers) should be considered "null" until further research provides specific biological or clinical evidence. Otherwise, all evidence supports its annotation as a non-coding transcript and not a protein/receptor target[2][3].
No known drugs targeting this transcript; mechanisms of action are thus not established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SMIM14 divergent transcript (SMIM14-DT).